Article Figures & Data
Figures
- Figure 1.
Effect of intranasal POH treatment in patients with astrocytoma grade II. Representative MRIs of AA-II patient (A) show a marked reduction of tumor size image after 2 years and 3 years of POH treatment in comparison with first image obtained before treatment. (B) Mild reduction of tumor size after 2 and 3 years of POH treatment in comparison with first image obtained before treatment.
- Figure 2.
Overall survival of glioma patients included in Phase I/II clinical trial. Kaplan-Meier curves show the influence of long-term treatment without discontinuation of intranasal POH administration. Comparison of primary GBM (A) and secondary GBM (p<0.0001); (B) anaplastic astrocytoma (AA) and anaplastic oligodendroglioma (p=0.0199). Line of tendency indicates survival rate of patients.
- Figure 3.
Effect of intranasal POH treatment in recurrent oligoastrocytoma. A patient with recurrent oligoastrocytoma and extensive peritumoral edema failed to respond to POH treatment. MRI image obtained before (A) and 4 months after POH treatment (B). A good-responder patient showed in comparison with initial MRI (C) a marked reduction (D) in the tumor size 4 years after POH treatment. HE staining (E) shows increased glomeruloid microvascular and glial cell proliferation with atipia, hypercromatism and nuclear pleomorphism. Brain biopsy fragment (F) obtained 4 years after intranasal POH treatment during intracranial drainage of hematoma shows apparently normal characteristics of glial and neuronal cellularity.
- Figure 4.
Effect of intranasal POH treatment in recurrent GBM. Representative brain image (MRI) of a patient with recurrent primary GBM. Decrease in the tumor size between the initial MRI (A, B) and 6 months after treatment (C, D).
- Figure 5.
Tumor recurrence after treatment discontinuation. Decrease in the tumor image size of a patient with secondary GBM at the time of inclusion in POH trial (A); image obtained 3 years after continuous treatment with intranasal POH (B); and image (C) obtained three months after the patient quit treatment.
Tables
In this issue
